AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (NYSE: ABBV) will invest $1.4 billion to build a new 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, supporting production of immunology, neuroscience and oncology medicines.
Construction begins in 2026 with completion expected by end of 2028, creating 734 full-time jobs and more than 2,000 construction jobs, and forming part of AbbVie's $100 billion U.S. R&D and capital commitment.
Allergan Aesthetics (NYSE: ABBV) partnered with entrepreneur Erin Lichy to share her Natrelle® breast augmentation journey on social media, aiming to normalize conversations about aesthetic surgery and support patient education.
The release highlights Natrelle®'s 50-year heritage, a 10-year clinical safety profile, implant options, and a nationwide Faces of Natrelle® testimonial program.
Haisco and AbbVie (NYSE: ABBV) entered an exclusive license agreement announced April 10, 2026, covering multiple pain compounds.
Haisco granted AbbVie global development, manufacturing, and commercialization rights excluding mainland China, Hong Kong, and Macau. Haisco will receive an upfront payment of USD $30 million, up to USD $715 million in milestones, and tiered royalties on future net sales.
Summary not available.
BOTOX Cosmetic (NYSE: ABBV) reopens applications for The Confidence Collective, running through April 29, 2026. The program will provide resources to 250 women entrepreneurs and award twenty $20,000 grants. Since 2023, the brand has awarded $1.2M to grant winners to support business growth and mentorship.
Selected cohort members will receive coaching, community access, and mentoring; grant winners will be announced this fall. Applicants must submit by April 29, 11:59 p.m. PT and agree to program terms.
Allergan Aesthetics (NYSE: ABBV) opened the new Allergan Medical Institute (AMI) Austin on April 7, 2026, its third U.S. AMI Training Center in the past year. The state-of-the-art facility offers immersive, hands-on education across facial injectables, body contouring, skincare, and regenerative medicine to advance clinical proficiency for providers.
AMI Austin emphasizes advanced injection techniques, complication management, practice development, and peer collaboration under Medical Director Dr. Saami Khalifian, supporting the company’s broader training network including Orange County and Atlanta centers.
Allergan Aesthetics (NYSE: ABBV) announced its fourth annual CoolMonth promotion running April 1–30, 2026, offering $400 off first-time CoolSculpting treatments for eligible Allē members and social giveaways up to $5,000.
CoolSculpting and CoolSculpting Elite are FDA-cleared for specific visible fat bulges and submental laxity; they are not weight-loss treatments. Entry and eligibility details apply.
Allergan Aesthetics (NYSE: ABBV) launched its fourth annual CoolMonth promotion for April 1–30, 2026, featuring a $400 discount for first-time CoolSculpting patients and Instagram giveaways up to $5,000.
Offers require Allē loyalty registration, are limited while supplies last, and CoolSculpting is described as an FDA-cleared, non‑surgical fat‑reduction treatment (not for weight loss).
AbbVie (NYSE: ABBV) will report first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens.
The company will host a live earnings webcast and conference call at 8:00 a.m. Central time accessible via AbbVie's investor relations website, with an archived edition available later that day.
Allergan Aesthetics (NYSE:ABBV) presented four e-posters at AAD on March 30, 2026, reporting Phase 3 and real-world aesthetics findings.
Key TrenibotE results: investigational serotype E showed rapid onset (as early as 8 hours), shorter duration (2–3 weeks), consistent efficacy across three repeat open-label treatments, a consistent safety profile, and no neutralizing antibody development.
GLP-1 patient insights: 52% expressed facial concerns; 32% were new to practices; top barriers were cost (82%) and fear of unnatural results (58%).